HOXA5 and neoplasm: Thus, to directly assess the anti-angiogenic potential of HoxA5 in a de novo tumor microenvironment in vivo, we generated an inducible, transgenic mouse using the TIE-2 promoter to restrict expression of a HoxA5 transgene largely to ECs, where transgene expression was suppressed until doxycycline withdrawal [12].